SEARCH

SEARCH BY CITATION

References

  • Amer, L., Kisiel, W., Searles, R.P., Williams, R.C. (1990) Impairment of the protein C anticoagulant pathway in a patient with systemic lupus erythematosus, anticardiolipin antibodies and thrombosis. Thrombosis Research, 57, 247258.
  • Aznar, J., Villa, P., Espana, F., Estelles, A., Grancha, S., Falco, C. (1997) Activated protein C resistance phenotype in patients with antiphospholipid antibodies. Journal of Laboratory and Clinical Medicine, 130, 202208.
  • Bernardi, F., Faioni, E.M., Castoldi, E., Lunghi, B., Castaman, G., Sacchi, E., Mannucci, P.M. (1997) A factor V genetic component differing from factor V R506Q contributes to the activated protein C resistance phenotype. Blood, 90, 15521557.
  • Bertina, R.M., Koeleman, B.P., Koster, T., Rosendaal, F.R., Dirven, R.J., De Ronde, H., Van Der Velden, P.A., Reitsma, P.H. (1994) Mutation in blood coagulation factor V associated with resistance to activated protein C. Nature, 369, 6467.
  • Bokarewa, M.I., Blomback, M., Egberg, N., Rosen, S. (1994) A new variant of interaction between phospholipid antibodies and the protein C system. Blood Coagulation and Fibrinolysis, 5, 3741.
  • Chae, C.U., Ridker, P.M., Manson, J.E. (1997) Postmenopausal hormone replacement therapy and cardiovascular disease. Thrombosis and Haemostasis, 78, 770780.
  • Clark, P., Brennand, J., Conkie, J.A., McCall, F., Greer, I.A., Walker, I.D. (1998) Activated protein C sensitivity, protein C, protein S and coagulation in normal pregnancy. Thrombosis and Haemostasis, 79, 11661170.
  • Clark, P., Walker, I.D., Greer, I. (1999) Acquired activated protein-C resistance in pregnancy and association with increased thrombin generation and fetal weight. Lancet, 353, 292293.
  • Clark, P., Sattar, N., Walker, I.D., Greer, I.A. (2001a) The Glasgow outcome, APCR and lipid (GOAL) pregnancy study: significance of pregnancy-associated activated protein C resistance. Thrombosis and Haemostasis, 85, 3035.
  • Clark, P., Rosing, J., Curvers, J., Tans, G., Conkie, J., Walker, I.D., Greer, I.A. (2001b) The Glasgow outcome, APC resistance and lipid (goal) pregnancy study: pregnancy-associated APC resistance. Thrombosis and Haemostasis, 86 (suppl.), 3002.
  • Colucci, M., Ciavarella, N., Giliberti, M.G., Semeraro, N. (1994) Resistance to activated protein C (APC): influence of factor V levels. Thrombosis and Haemostasis, 72, 987988.
  • Curvers, J., Christella, M., Thomassen, L.G.D., Nicolaes, G.A.F., Van Oerle, R., Hamulyak, K., Hemker, H.C., Tans, G., Rosing, J. (1999) Acquired APC resistance and oral contraceptives: difference between two functional tests. British Journal of Haematology, 105, 8894.
  • Dahlback, B., Carlsson, M., Svensson, P.J. (1993) Familial thrombophilia due to a previously unrecognized mechanism characterized by poor anticoagulant response to activated protein C: prediction of a cofactor to activated protein C. Proceedings of the National Academy of Sciences of the USA, 90, 10041008.
  • Dati, F., Hafner, G., Erbes, H., Prellwitz, W., Kraus, M., Niemann, F., Noah, M., Wagner, C. (1997) ProC Global: the first functional screening assay for the complete protein C pathway. Clinical Chemistry, 43, 17191723.
  • De Ronde, H. & Bertina, R.M. (1994) Laboratory diagnosis of APC-resistance: a critical evaluation of the test and the development of diagnostic criteria. Thrombosis and Haemostasis, 72, 880886.
  • De Visser, M.C., Rosendaal, F.R., Bertina, R.M. (1999) A reduced sensitivity for activated protein C in the absence of factor V Leiden increases the risk of venous thrombosis. Blood, 93, 12711276.
  • De Visser, M.C., Guasch, J.F., Kamphuisen, P.W., Vos, H.L., Rosendaal, F.R., Bertina, R.M. (2000) The HR2 haplotype of factor V: effects on factor V levels, normalized activated protein C sensitivity ratios and the risk of venous thrombosis. Thrombosis and Haemostasis, 83, 577582.
  • Dizon-Townson, D.S., Nelson, L.M., Easton, K., Ward, K. (1996) The factor V Leiden mutation may predispose women to severe preeclampsia. American Journal of Obstetrics and Gynecology, 175, 902905.
  • Eichinger, S., Weltermann, A., Philipp, K., Hafner, E., Kaider, A., Kittl, E.M., Brenner, B., Mannhalter, C., Lechner, K., Kyrle, P.A. (1999) Prospective evaluation of hemostatic system activation and thrombin potential in healthy pregnant women with and without factor V Leiden. Thrombosis and Haemostasis, 82, 12321236.
  • Emerson, P.A. & Marks, P. (1977) Preventing thromboembolism after myocardial infarction: effect of low-dose heparin or smoking. British Medical Journal, 1, 1820.
  • Freyburger, G., Bilhou-Nabera, C., Dief, S., Javorschi, S., Labrouche, S., Lerebeller, M.J., Boisseau, M.R. (1996) Technical and biological conditions influencing the functional APC resistance test. Thrombosis and Haemostasis, 75, 460465.
  • Freyburger, G., Javorschi, S., Labrouche, S., Bernard, P. (1997) Proposal for objective evaluation of the performance of various functional APC-resistance tests in genotyped patients. Thrombosis and Haemostasis, 78, 13601365.
  • Gable, P.S., Le, D.T., McGehee, W., Rapaport, S.I. (1997) A Protac-based screening test for activated protein C-resistant factor Va and other defects of the protein C anticoagulant pathway. Blood Coagulation and Fibrinolysis, 8, 327335.
  • Goldhaber, S.Z., Grodstein, F., Stampfer, M.J., Manson, J.E., Colditz, G.A., Speizer, F.E., Willet, W.C., Hennekens, C.H. (1997) A prospective study of risk factors in pulmonary embolism in women. Journal of the American Medical Association, 277, 642645.
  • Griffin, J.H., Evatt, B., Wideman, C., Fernandez, J.A. (1993) Anticoagulant protein C pathway defective in majority of thrombophilic patients. Blood, 82, 19891993.
  • Hampton, K.K., Preston, F.E., Greaves, M. (1994) Resistance to activated protein C. New England Journal of Medicine, 331, 130.
  • Henkens, C.M.A., Bom, V.J., Seinen, A.J., Van Der Meer, J. (1995) Sensitivity to activated protein C: influence of oral contraceptives and sex. Thrombosis and Haemostasis, 73, 402404.
  • Jorquera, J.I., Montoro, J.M., Fernandez, M.A., Aznar, J.A., Aznar, J. (1994) Modified test for activated protein C resistance. Lancet, 344, 11621163.
  • Kawasaki, T., Kambayashi, J., Sakon, M. (1995) Hyperlipidemia: a novel etiologic factor in deep vein thrombosis. Thrombosis Research, 79, 147151.
  • Kawasaki, T., Kambayashi, J.I., Ariyoshi, H., Sakon, M., Suehisa, E., Mondedn, M. (1997) Hypercholesterolemia as a risk factor for deep-vein thrombosis. Thrombosis Research, 88, 6773.
  • Kearon, C., Gent, M., Hirsh, J., Wietz, J., Kovacs, M.J., Anderson, D.R., Turpie, A.G., Green, D., Ginsberg, J.S., Wells, P., Mackinnon, B., Julian, J.A. (1999) A comparison of three months of anticoagulation with extended anticoagulation for a first episode of idiopathic venous thromboembolism. New England Journal of Medicine, 340, 901907.
  • Kiechl, S., Muigg, A., Santer, P., Mitterer, M., Egger, G., Oberhollenzer, M., Oberhollenzer, F., Mayr, A., Gasperi, A., Poewe, W., Willeit, J. (1999) Poor response to activated protein C as a prominent risk predictor of advanced atherosclerosis and arterial disease. Circulation, 99, 614619.
  • Klonoff-Cohen, H., Edelstein, S., Savitz, D. (1993) Cigarette smoking and preeclampsia. Obstetrics and Gynecology, 81, 541544.
  • Kluft, C., Meijer, P., Gram, J., Jesperson, J. (1999) Acquired activated protein C resistance. Lancet, 353, 1882.
  • Koefoed, B.G., Feddersen, C., Gullov, A.L., Petersen, P. (1997) Effect of fixed minidose warfarin, conventional dose warfarin and aspirin on INR and prothrombin fragment 1 + 2 in patients with atrial fibrillation. Thrombosis and Haemostasis, 77, 845848.
  • Koster, T., Rosendaal, F.R., De Ronde, H., Briet, E., Vandenbroucke, J.P., Bertina, R.M. (1993) Venous thrombosis due to poor anticoagulant response to activated protein C: Leiden Thrombophilia Study. Lancet, 342, 15031506.
  • Koster, T., Blann, A.D., Briet, E., Vandenbroucke, J.P., Rosendaal, F.R. (1995) Role of clotting factor VIII in effect of von Willebrand factor on occurrence of deep-vein thrombosis. Lancet, 345, 152155.
  • Kraaijenhagen, R.A., In'T Anker, P.S., Koopman, M.M.W., Reitsma, P.H., Prins, M.H.H., Van Den Ende, A., Buller, H.R. (2000) High plasma concentration of factor VIIIc is a major risk factor for venous thromboembolism. Thrombosis and Haemostasis, 83, 59.
  • Kraus, M., Noah, M., Fickenscher, K. (1995) The PCAT – a simple screening assay for assessing the functionality of the protein C anticoagulant pathway. Thrombosis Research, 79, 217222.
  • Laffan, M.A. & Manning, R. (1996) The influence of factor VIII on measurement of activated protein C resistance. Blood Coagulation and Fibrinolysis, 7, 761765.
  • Le, D.T., Griffin, J.H., Greengard, J.S., Mujumdar, V., Rapaport, S.I. (1995) Use of a generally applicable tissue factor – dependent factor V assay to detect activated protein C-resistant factor Va in patients receiving warfarin and in patients with a lupus anticoagulant. Blood, 85, 17041711.
  • Lowe, G.D.O., Rumley, A., Woodward, M., Morrison, C.E., Philippou, H., Lane, D.A., Tunstall-Pedoe, H. (1997) Epidemiology of coagulation factors, inhibitors and activation markers: The third Glasgow MONICA survey 1. Illustrative reference ranges by age, sex and hormone use. British Journal of Haematology, 97, 775784.
  • Lowe, G.D.O., Rumley, A., Woodward, M., Reid, E., Rumley, J. (1999) Activated protein C resistance and the FV:R506Q mutation in a random population sample-associations with cardiovascular risk factors and coagulation variables. Thrombosis and Haemostasis, 81, 918924.
  • MacCallum, P.K., Cooper, J.A., Martin, J., Howarth, D.J., Meade, T.W., Miller, G.J. (2000) Haemostatic and lipid determinants of prothrombin fragment F1+2 and d-dimer in plasma. Thrombosis and Haemostasis, 83, 421426.
  • Marks, P. & Emerson, P.A. (1974) Increased incidence of deep vein thrombosis after myocardial infarction in non-smokers. British Medical Journal, 3, 232234.
  • Martinelli, I., Bottasso, B., Duca, F., Faioni, E., Mannucci, P.M. (1996) Heightened thrombin generation in individuals with resistance to activated protein C. Thrombosis and Haemostasis, 75, 703705.
  • Martinelli, I., Taioli, E., Cetin, I., Marinani, A., Gerosa Silla, V., Bozzo, M., Mannucci, P.M. (2000) Mutations in coagulation factors in women with unexplained late pregnancy loss. New England Journal of Medicine, 343, 10151018.
  • Martinuzzo, M., Forastiero, R., Adamczuk, Y., Cerrato, G., Carreras, L.O. (1996) Activated protein C resistance in patients with anti-beta2 glycoprotein-I antibodies. Blood Coagulation and Fibrinolysis, 7, 702704.
  • Mathonet, F., De Mazancourt, P., Denninger, M.-H., Morot, M., Bennattar, N., Giudicelli, Y. (1996) Role of factor VIII on activated protein C resistance ratio in inflammatory diseases. British Journal of Haematology, 95, 423425.
  • Meade, T.W. (1997) Hormone replacement therapy and haemostatic function. Thrombosis and Haemostasis, 78, 765769.
  • Meade, T.W., Cooper, J.A., Stirling, Y., Howarth, D.J., Ruddock, V., Miller, G.J. (1994) Factor VIII, ABO blood group and the incidence of ischaemic heart disease. British Journal of Haematology, 88, 601607.
  • Nebulsi, A.A., Folsom, A.R., White, A., Patsch, W., Heiss, G., Wu, K.K., Szklo, M. (1993) Association of hormone-replacement therapy with various cardiovascular risk factors in post-menopausal women. New England Journal of Medicine, 328, 10691075.
  • Nicolaes, G.A., Thomassen, M.C., Van Oerle, R., Hamulyak, K., Hemker, H.C., Tans, G., Rosing, J. (1996) A prothrombinase-based assay for detection of resistance to activated protein C. Thrombosis and Haemostasis, 76, 404410.
  • Nicolaes, G.A., Thomassen, M.C., Tans, G., Rosing, J., Hemker, H.C. (1997) Effect of activated protein C on thrombin generation and on the thrombin potential in plasma of normal and APC-resistant individuals. Blood Coagulation and Fibrinolysis, 8, 2838.
  • Olivieri, O., Friso, S., Manzato, F., Guella, A., Bernardi, F., Lunghi, B., Girelli, D., Azzini, M., Brocco, G., Russo, C. (1995) Resistance to activated protein C in healthy women taking oral contraceptives. British Journal of Haematology, 91, 465470.
  • Oosting, J.D., Derksen, R.H., Bobbink, I.W., Hackeng, T.M., Bouma, B.N., De Groot, P.G. (1993) Antiphospholipid antibodies directed against a combination of phospholipids with prothrombin, protein C, or protein S: an explanation for their pathogenic mechanism. Blood, 81, 26182625.
  • Osterud, B., Robertsen, R., Asvang, G.B., Thijssen, F. (1994) Resistance to activated protein C is reduced in women using oral contraceptives. Blood Coagulation and Fibrinolysis, 5, 853854.
  • Prescott, R.J., Jones, D.R., Vailescu, C., Henderson, J.T., Ruckley, C.V. (1978) Smoking and risk factors in deep vein thrombosis. Thrombosis and Haemostasis, 40, 128133.
  • Ridker, P.M., Miletich, J.P., Stampfer, M.J., Goldhaber, S.Z., Lindpaintner, K., Hennekens, C.H. (1995) Factor V Leiden and risks of recurrent idiopathic venous thromboembolism. Circulation, 92, 28002802.
  • Rintelen, C., Pabinger, I., Knobl, P., Lechner, K., Mannhalter, C. (1996) Probability of recurrence of thrombosis in patients with and without factor V Leiden. Thrombosis and Haemostasis, 75, 229232.
  • Ripoll, L., Mazoyer, E., Baudin, B., Lacam, S., Varsat, B., Drouet, L.O. (1998) Can high plasma ceruloplasmin levels cause acquired activated protein C resistance? Thrombosis and Haemostasis, 79, 449450.
  • Rosing, J., Tans, G., Nicolaes, G.A., Thomassen, M.C., Van Oerle, R., Van Der Ploeg, P.M., Heijnen, P., Hamulyak, K., Hemker, H.C. (1997) Oral contraceptives and venous thrombosis: different sensitivities to activated protein C in women using second- and third-generation oral contraceptives. British Journal of Haematology, 97, 233238.
  • Schramm, W. & Heinemann, L.A. (1997) Oral contraceptives and venous thromboembolism: acquired APC resistance? British Journal of Haematology, 98, 491492.
  • Simioni, P., Scarano, L., Gavasso, S., Sardella, C., Girolami, B., Scudeller, A., Girolami, A. (1996) Prothrombin fragment 1+2 and thrombin-antithrombin complex levels in patients with inherited APC resistance due to factor V Leiden mutation. British Journal of Haematology, 92, 435441.
  • Simioni, P., Prandoni, P., Lensing, A.W., Scudeller, A., Sardella, C., Prins, M.H., Villalta, S., Dazzi, F., Girolami, A. (1997) The risk of recurrent venous thromboembolism in patients with an Arg506[RIGHTWARDS ARROW]Gln mutation in the gene for factor V (factor V Leiden). New England Journal of Medicine, 336, 399403.
  • Takahashi, H., Wada, K., Satoh, N., Takakuwa, E., Furuta, R., Yoshino, N., Shibata, A. (1993) Evaluation of oral anticoagulant therapy by measuring plasma prothrombin fragment 1 + 2. Blood Coagulation and Fibrinolysis, 4, 435439.
  • Talbot, S., Wakley, E.J., Langman, M.J.S. (1972) A1, A2, B, and O blood groups, Lewis blood groups and serum triglyceride and cholesterol concentrations in patients with venous thromboembolic disease. Lancet, 11521154.
  • Taube, J., McWilliam, N., Luddington, R., Byrne, C.D., Baglin, T. (1999) Activated protein C resistance: effect of platelet activation, platelet-derived microparticles and atherogenic lipoproteins. Blood, 93, 37923797.
  • Tosetto, A., Missiaglia, E., Gatto, E., Rodeghiero, F. (1997) The VITA project: phenotypic resistance to activated protein C and FV Leiden mutation in the general population. Vicenza thrombophilia and atherosclerosis. Thrombosis and Haemostasis, 78, 859863.
  • Tosetto, A., Castaman, G., Cappellari, A., Rodeghiero, F. (2000) The VITA Project: heritability of resistance to activated protein C. Thrombosis and Haemostasis, 84, 811814.
  • Van Baal, W.M., Emeis, J.J., Van Der Mooren, M.J., Kessel, H., Kenemans, P., Stehouwer, C.D.A. (2000) Impaired procoagulant–anticoagulant balance during hormone replacement therapy? A randomised, placebo-controlled 12 week study. Thrombosis and Haemostasis, 83, 2934.
  • Vandenbroucke, J.P. & Rosendaal, F.R. (1997) End of the line for ‘third-generation-pill’ controversy? Lancet, 349, 11131114.
  • Vandenbroucke, J.P., Rosing, J., Bloemenkamp, K.W.M., Middledorp, S., Helmerhorst, F.M., Bouma, B.N., Rosendaal, F.R. (2001) Oral contraceptives and the risk of venous thrombosis. New England Journal of Medicine, 344, 15271535.
  • Van Der Bom, J.G., Bots, M.L., Haverkate, F., Slagboom, P.E., Meijer, P., De Jong, P.T., Hofman, A., Grobbee, D.E., Kluft, C. (1996) Reduced response to activated protein C is associated with increased risk for cerebrovascular disease. Annals of Internal Medicine, 125, 265269.
  • Van Der Velde, W.J. & Treffers, P.E. (1985) Smoking in pregnancy: the influence on percentile birth weight, mean birth weight, placental weight, menstrual age, perinatal mortality and maternal diastolic blood pressure. Gynecology and Obstetric Investigation, 19, 5763.
  • Van Hylckama Vlieg, A., Van Der Linden, I.K., Bertina, R.M., Rosendaal, F.R. (2000) High levels of factor IX increase the risk of venous thrombosis. Blood, 95, 36783682.
  • Varadi, K., Moritz, B., Lang, H., Bauer, K., Preston, E., Peake, I., Rivard, G.E., Keil, B., Schwarz, H.P. (1995) A chromogenic assay for activated protein C resistance. British Journal of Haematology, 90, 884891.
  • Williamson, D., Brown, K., Luddington, R., Baglin, C., Baglin, T. (1998) Factor V Cambridge: a new mutation (Arg306[RIGHTWARDS ARROW]Thr) associated with resistance to activated protein C. Blood, 91, 11401144.
  • Winkler, U.H. (1998) Effects of hemostatic variables of desogestrel- and gestodene-containing oral contraceptives in comparison with levonorgestrel-containing oral contraceptives: a review. American Journal of Obstetrics and Gynecology, 179, 51S61S.
  • Woodward, M., Lowe, J.D.O., Rumely, A., Tunstall-Pedoe, H., Philippou, H., Lane, D.A., Morrison, C.E. (1997) Epidemiology of coagulation factors, inhibitors and activation markers: the third Glasgow MONICA survey. Relationship to cardiovascular risk factors and prevalent cardiovascular disease. British Journal of Haematology, 97, 785797.